Oxytocin Alternatives For Postpartum Hemorrhage Prevention In Births

Key Takeaways

• Pooled findings suggested clearer benefits in cesarean than in vaginal birth for blood loss and postpartum hemorrhage outcomes.
• Hemoglobin variation was lower in both vaginal and cesarean analyses.
• The evidence was described as indicative rather than conclusive because heterogeneity was substantial and many pooled results were not significant.

A systematic review and meta-analysis of oxytocin alternatives for postpartum hemorrhage prevention found a significant reduction in cesarean hemorrhage occurrence, with a pooled odds ratio of 0.58. Comparisons of tranexamic acid, carbetocin, and misoprostol with oxytocin spanned both vaginal and cesarean births. In vaginal births, pooled results for blood loss and postpartum hemorrhage occurrence were not statistically significant. The overall pattern was more consistent in cesarean than in vaginal birth.

The study evaluated randomized trials comparing tranexamic acid, carbetocin, and misoprostol with oxytocin for postpartum hemorrhage prevention in vaginal and cesarean births. Searches covered SCOPUS, PubMed, Web of Science, and the Cochrane Library from January 2015 through February 2025. The review followed Cochrane guidance and PRISMA, and the protocol was registered through PROSPERO registration CRD420251002602. Twenty trials were included, with pooled outcomes analyzed separately by delivery mode.

In vaginal birth analyses, pooled blood loss was not significantly different, with SMD −0.21 and a 95% confidence interval from −0.62 to 0.19; heterogeneity was high at I2 96%. Vaginal postpartum hemorrhage occurrence was also not significant, with OR 0.80 and a 95% confidence interval from 0.53 to 1.21; I2 reached 98%. In cesarean births, pooled blood loss favored the alternatives, with SMD −0.82 and a 95% confidence interval from −1.49 to −0.16, with p=0.02, while postpartum hemorrhage occurrence was lower at OR 0.58 with a 95% confidence interval from 0.43 to 0.80 and I2 21%. Hemoglobin variation was lower in vaginal analyses, SMD −0.32 with a 95% confidence interval from −0.49 to −0.16 and I2 93%, and in cesarean analyses, SMD −0.90 with a 95% confidence interval from −1.52 to −0.27 and I2 96%.

The authors described these findings as indicative rather than conclusive, citing substantial heterogeneity and the predominance of non-significant pooled results. Very high inconsistency in several analyses limited confidence in the pooled estimates despite significant cesarean findings. They called for further randomized controlled trials to clarify effectiveness, optimize dosing, and identify patient groups most likely to benefit. Their interpretation remained cautious even where pooled cesarean results favored the alternatives.